ArticleDiscover oncology2025
Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The glioma neuron symbiosis hypothesis-cellular and molecular mechanistic considerations.Frontiers in neuroscience · 2026Article
- Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aimed to analyze the prognostic and diagnostic value of Lactate dehydrogenase A (LDHA) and solute carrier family 16 member 1 (SLC16A1) in low-grade gliomas (LGG).
methodsGene expression datasets for LGG were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) databases. The prognostic value of LDHA and SLC16A1 in LGG was analyzed using the survival package. Receiver operating characteristic (ROC) curves were drawn to evaluate the ability of the model to distinguish between patients with LGG and controls. Gene set enrichment analysis (GSEA) of single gene was utilized to explore the potential biological function of the two genes. The protein levels of LDHA and SLC16A1 were analyzed using the Human Protein Atlas database. LDHA and SLC16A1 expression was verified using real-time reverse transcription polymerase chain reaction. Finally, the effects of low SLC16A1 expression on the proliferation, migration, and invasion of LGG cells were investigated using CCK-8 and Transwell assays.
resultsLDHA was downregulated, and SLC16A1 was upregulated in LGG tissues compared to normal tissues in TCGA dataset. Kaplan-Meier (K-M) survival and ROC curves revealed that these two genes have potential prognostic and diagnostic performances. LDHA positively correlated with SLC16A1 in TCGA and CGGA cohorts. GSEA demonstrated that LDHA is involved in the chemokine and NOD-like receptor signaling pathways, whereas SLC16A1 is involved in the JAK-STAT and NOD-like receptor signaling pathways. Immunohistochemical profiles of LDHA and SLC16A1 were consistent with their mRNA expression levels. SLC16A1 overexpression and downregulation of LDHA have been validated in glioma cell lines. Additionally, low SLC16A1 expression inhibited the proliferation, migration, and invasion of glioma cells.
conclusionLDHA and SLC16A1 have potential prognostic and diagnostic values for LGG. Therefore, SLC16A1 may serve as a potential biomarker for the diagnosis and treatment of LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.